Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Oct;64(10):4074–4077. doi: 10.1128/iai.64.10.4074-4077.1996

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

D Cohen 1, S Ashkenazi 1, M Green 1, Y Lerman 1, R Slepon 1, G Robin 1, N Orr 1, D N Taylor 1, J C Sadoff 1, C Chu 1, J Shiloach 1, R Schneerson 1, J B Robbins 1
PMCID: PMC174339  PMID: 8926071

Abstract

The safety and immunogenicity of investigational conjugates, composed of the O-specific polysaccharides of Shigella sonnei and Shigella flexneri type 2a covalently bound to Pseudomonas aeruginosa recombinant exoprotein A (rEPA), were evaluated in 192 Israeli soldiers. None had significant local reactions or fever. Fourteen days after injection, 90% of S. sonnei-rEPA recipients and 73 to 77% of S. flexneri-rEPA recipients had a fourfold or greater increase in serum immunoglobulin G (IgG) and IgA anti-lipopolysaccharide (anti-LPS) levels; at 2 years, these remained higher than at prevaccination (P < 0.01). There was a fourfold or greater increase in IgM anti-LPS in 20% of vaccinees at 2 weeks, but levels returned to prevaccination values at 6 to 12 months. IgG was the highest and most sustained class of LPS antibodies. Reinjection at day 42 did not boost antibody levels. Eighteen of 23 (78%) who received S. sonnei-rEPA and 13 of 19 (68%) who received S. flexneri-rEPA. had significant IgA-secreting cell responses. Significant IgG antibody-secreting cell responses were detected in 19 of 23 (83%) and 11 of 19 (58%) volunteers following vaccination with S. sonnei-rEPA and S. flexneri 2a-rEPA, respectively. On the basis of these data, further evaluation of the Shigella conjugates for protective efficacy in field trials in Israel was started.

Full Text

The Full Text of this article is available as a PDF (176.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashkenazi S., May-Zahav M., Dinari G., Gabbay U., Zilberberg R., Samra Z. Recent trends in the epidemiology of Shigella species in Israel. Clin Infect Dis. 1993 Nov;17(5):897–899. doi: 10.1093/clinids/17.5.897. [DOI] [PubMed] [Google Scholar]
  2. Chu C. Y., Liu B. K., Watson D., Szu S. S., Bryla D., Shiloach J., Schneerson R., Robbins J. B. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun. 1991 Dec;59(12):4450–4458. doi: 10.1128/iai.59.12.4450-4458.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohen D., Block C., Green M. S., Lowell G., Ofek I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J Clin Microbiol. 1989 Jan;27(1):162–167. doi: 10.1128/jcm.27.1.162-167.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen D., Green M. S., Block C., Rouach T., Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis. 1988 May;157(5):1068–1071. doi: 10.1093/infdis/157.5.1068. [DOI] [PubMed] [Google Scholar]
  5. Cohen D., Green M. S., Block C., Slepon R., Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol. 1991 Feb;29(2):386–389. doi: 10.1128/jcm.29.2.386-389.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohen D., Green M., Block C., Slepon R., Ambar R., Wasserman S. S., Levine M. M. Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet. 1991 Apr 27;337(8748):993–997. doi: 10.1016/0140-6736(91)92657-n. [DOI] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Sadoff J. C., Fürer E. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans. Infect Immun. 1988 Jul;56(7):1829–1830. doi: 10.1128/iai.56.7.1829-1830.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. DuPont H. L., Hornick R. B., Dawkins A. T., Snyder M. J., Formal S. B. The response of man to virulent Shigella flexneri 2a. J Infect Dis. 1969 Mar;119(3):296–299. doi: 10.1093/infdis/119.3.296. [DOI] [PubMed] [Google Scholar]
  9. DuPont H. L., Levine M. M., Hornick R. B., Formal S. B. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis. 1989 Jun;159(6):1126–1128. doi: 10.1093/infdis/159.6.1126. [DOI] [PubMed] [Google Scholar]
  10. Ekwall E., Haeggmann S., Kalin M., Svenungsson B., Lindberg A. A. Antibody response to Shigella sonnei infection determined by an enzyme-linked immunosorbent assay. Eur J Clin Microbiol. 1983 Jun;2(3):200–205. doi: 10.1007/BF02029516. [DOI] [PubMed] [Google Scholar]
  11. Granoff D. M., Shackelford P. G., Pandey J. P., Boies E. G. Antibody responses to Haemophilus influenzae type b polysaccharide vaccine in relation to Km(1) and G2m(23) immunoglobulin allotypes. J Infect Dis. 1986 Aug;154(2):257–264. doi: 10.1093/infdis/154.2.257. [DOI] [PubMed] [Google Scholar]
  12. Green M. S., Block C., Cohen D., Slater P. E. Four decades of shigellosis in Israel: epidemiology of a growing public health problem. Rev Infect Dis. 1991 Mar-Apr;13(2):248–253. doi: 10.1093/clinids/13.2.248. [DOI] [PubMed] [Google Scholar]
  13. Green M. S., Cohen D., Block C., Rouach Z., Dycian R. A prospective epidemiologic study of shigellosis in the Israel Defense Forces: implications for the use of shigella vaccines. Isr J Med Sci. 1987 Jul;23(7):811–815. [PubMed] [Google Scholar]
  14. Henry F. J., Alam N., Aziz K. M., Rahaman M. M. Dysentery, not watery diarrhoea, is associated with stunting in Bangladeshi children. Hum Nutr Clin Nutr. 1987 Jul;41(4):243–249. [PubMed] [Google Scholar]
  15. Herrington D. A., Van de Verg L., Formal S. B., Hale T. L., Tall B. D., Cryz S. J., Tramont E. C., Levine M. M. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990 Aug;8(4):353–357. doi: 10.1016/0264-410x(90)90094-3. [DOI] [PubMed] [Google Scholar]
  16. Lue C., Prince S. J., Fattom A., Schneerson R., Robbins J. B., Mestecky J. Antibody-secreting peripheral blood lymphocytes induced by immunization with a conjugate consisting of Streptococcus pneumoniae type 12F polysaccharide and diphtheria toxoid. Infect Immun. 1990 Aug;58(8):2547–2554. doi: 10.1128/iai.58.8.2547-2554.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Miller M. A., Meschievitz C. K., Ballanco G. A., Daum R. S. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics. 1995 Apr;95(4):522–527. [PubMed] [Google Scholar]
  18. Orr N., Robin G., Lowell G., Cohen D. Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei. J Clin Microbiol. 1992 Aug;30(8):2165–2168. doi: 10.1128/jcm.30.8.2165-2168.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Robbins J. B., Chu C., Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis. 1992 Aug;15(2):346–361. doi: 10.1093/clinids/15.2.346. [DOI] [PubMed] [Google Scholar]
  20. Robbins J. B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis. 1990 May;161(5):821–832. doi: 10.1093/infdis/161.5.821. [DOI] [PubMed] [Google Scholar]
  21. Schneerson R., Robbins J. B., Parke J. C., Jr, Bell C., Schlesselman J. J., Sutton A., Wang Z., Schiffman G., Karpas A., Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 1986 May;52(2):519–528. doi: 10.1128/iai.52.2.519-528.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smollan G., Block C. Development of antimicrobial drug resistance among Shigellas isolated at an Israeli hospital from 1977 through 1990. Public Health Rev. 1990;18(4):319–327. [PubMed] [Google Scholar]
  23. Taylor D. N., Echeverria P., Pál T., Sethabutr O., Saiborisuth S., Sricharmorn S., Rowe B., Cross J. The role of Shigella spp., enteroinvasive Escherichia coli, and other enteropathogens as causes of childhood dysentery in Thailand. J Infect Dis. 1986 Jun;153(6):1132–1138. doi: 10.1093/infdis/153.6.1132. [DOI] [PubMed] [Google Scholar]
  24. Taylor D. N., Trofa A. C., Sadoff J., Chu C., Bryla D., Shiloach J., Cohen D., Ashkenazi S., Lerman Y., Egan W. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun. 1993 Sep;61(9):3678–3687. doi: 10.1128/iai.61.9.3678-3687.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES